Description:
Organized by EORTC, National Cancer Institute, European Medicines Agency, and American Association for Cancer Research, IBCD 2016 offers a unique program focusing on multi-stakeholder approaches to cancer drug development with new cancer biomarkers. IBCD will address how all this impacts drug development and companion diagnostics with particular attention on biomarker validation, quality assurance and control, the limitations of genomic profiling, regulatory acceptance, interpretation of next generation sequencing results, challenges associated with immunological, functional and imaging biomarkers, as well as new challenges for statistics and bioinformatics.

Website

Event Organizer & Secretariat:
EORTC
Avenue Emmanuel Mounier, 83
Brussels 1200
Belgium

Phone +32 774 10 86
Fax +327 772 35 45
events[at]eortc.be